Sharon E Fox

Dr. Sharon E Fox

orcid

Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 July 2020 in The Lancet Respiratory Medicine
Verified
Journal Article
Closed access
SFSharon E Fox
Sharon E Fox
AAAibek Akmatbekov
Aibek Akmatbekov
JHJack L Harbert
Jack L Harbert
GLGuang Li
Guang Li
JBJ Quincy Brown
J Quincy Brown
RHRichard S Vander Heide
Richard S Vander Heide

15 December 2021 in Journal of Clinical Investigation
Verified
Journal Article
Closed access
PDF file
JKJason Knight
Jason Knight
RCRoberto Caricchio
Roberto Caricchio
JCJean-Laurent Casanova
Jean-Laurent Casanova
ACAlexis J. Combes
Alexis J. Combes
BDBetty Diamond
Betty Diamond
WMWilliam J. McCune
William J. McCune
Acute COVID-19, caused by SARS-CoV-2, is characterized by diverse clinical presentations, ranging from asymptomatic infection to fatal respiratory failure, and often associated with varied longer-term sequelae. Over the past 18 months, it has become apparent that inappropriate immune responses contribute to the pathogenesis of severe COVID-19. Researchers working at the intersection of COVID-19 and autoimmunity recently gathered at an American Autoimmune Related Diseases Association Noel R. Rose Colloquium to address the current state of knowledge regarding two important questions: Does established autoimmunity predispose to severe COVID-19? And, at the same time, can SARS-CoV-2 infection trigger de novo autoimmunity? Indeed, work to date has demonstrated that 10% to 15% of patients with critical COVID-19 pneumonia exhibit autoantibodies against type I interferons, suggesting that preexisting autoimmunity underlies severe disease in some patients. Other studies have identified functional autoantibodies following infection with SARS-CoV-2, such as those that promote thrombosis or antagonize cytokine signaling. These autoantibodies may arise from a predominantly extrafollicular B cell response that is more prone to generating autoantibody-secreting B cells. This Review highlights the current understanding, evolving concepts, and unanswered questions provided by this unique opportunity to determine mechanisms by which a viral infection can be exacerbated by, and even trigger, autoimmunity. The potential role of autoimmunity in post-acute sequelae of COVID-19 is also discussed.

15 December 2020 in Annals of Internal Medicine
Verified
Journal Article
Open access
SFSharon E Fox
Sharon E Fox
FLFernanda S. Lameira
Fernanda S. Lameira
ERElizabeth B. Rinker
Elizabeth B. Rinker
RHRichard S. Vander Heide
Richard S. Vander Heide

1 September 2021 in Cardiovascular Pathology
Verified
Journal Article
Closed access
SFSharon E Fox
Sharon E Fox
LFLacey Falgout
Lacey Falgout
RHRichard S. Vander Heide
Richard S. Vander Heide

17 April 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
GLGuang Li
Guang Li
SFSharon E Fox
Sharon E Fox
BSBrian Summa
Brian Summa
BHBihe Hu
Bihe Hu
CWCarola Wenk
Carola Wenk
JBJ. Quincy Brown
J. Quincy Brown
The study of pulmonary samples from individuals who have died as a direct result of COVID-19 infection is vital to our understanding of the pathogenesis of this disease. Histopathologic studies of lung tissue from autopsy of patients with COVID-19 specific mortality are only just emerging. All existing reports have relied on traditional 2-dimensional slide-based histological methods for specimen preparation. However, emerging methods for high-resolution, massively multiscale imaging of tissue microstructure using fluorescence labeling and tissue clearing methods enable the acquisition of tissue histology in 3-dimensions, that could open new insights into the nature of SARS-Cov-2 infection and COVID-19 disease processes. In this article, we present the first 3-dimensional images of lung autopsy tissues taken from a COVID-19 patient, including 3D “virtual histology” of cubic-millimeter volumes of the diseased lung, providing unique insights into disease processes contributing to mortality that could inform frontline treatment decisions.

1 April 2025 in JCI Insight
Verified
Journal Article
Open access
PDF file
ETEliza Pei-Suen Tsou
Eliza Pei-Suen Tsou
RARamadan A. Ali
Ramadan A. Ali
CLChenyang Lu
Chenyang Lu
GSGautam Sule
Gautam Sule
CCCarmelo Carmona-Rivera
Carmelo Carmona-Rivera
DFDavid Fox
David Fox
The soluble variant of the ectopeptidase CD13 (sCD13), released from the cell surface by matrix metalloproteinase 14 (MMP14), is a potent pro-inflammatory mediator, displaying chemotactic, angiogenic, and arthritogenic properties through bradykinin receptor B1 (B1R). We revealed a link between sCD13 and amplified neutrophil-mediated inflammatory responses in SARS-CoV-2 infection. sCD13 was markedly elevated in patients with COVID-19 and correlated with disease severity and variants, ethnicity, inflammation markers, and neutrophil extracellular trap formation (NETosis). Neutrophils treated with sCD13 showed heightened NETosis and chemotaxis, which were inhibited by sCD13 receptor blockade. Meanwhile sCD13 did not induce platelet aggregation. Single-cell analysis of COVID-19 lungs revealed coexpression of CD13 and MMP14 by various cell types, and higher CD13 expression compared with controls. Neutrophils with high CD13 mRNA were enriched for genes associated with immaturity, though CD13 protein expression was lower. Histological examination of COVID-19 lungs revealed CD13-positive leukocytes trapped in vessels with fibrin thrombi. Flow cytometry verified the presence of B1R and a second sCD13 receptor, protease-activated receptor 4, on monocytes and neutrophils. These findings identify sCD13 as a potential instigator of COVID-19–associated NETosis, potentiating vascular stress and thromboembolic complications. The potent pro-inflammatory effects of sCD13 may contribute to severe COVID-19, suggesting that sCD13 and its receptors might be therapeutic targets.